Efficacy of QuickSleeper Intraosseous Injection of 4% Articaine in Mandibular First Molars With Symptomatic Irreversible Pulpitis: A Randomized Controlled Trial.

Anesthesia progress Pub Date : 2024-09-09 DOI:10.2344/363591

Mohammadreza Vatankhah, Omid Dianat, Nazanin Zargar, Saeid Gharibian Bejestani, Alireza Akbarzadeh Baghban, Shiva Shojaeian

{"title":"Efficacy of QuickSleeper Intraosseous Injection of 4% Articaine in Mandibular First Molars With Symptomatic Irreversible Pulpitis: A Randomized Controlled Trial.","authors":"Mohammadreza Vatankhah, Omid Dianat, Nazanin Zargar, Saeid Gharibian Bejestani, Alireza Akbarzadeh Baghban, Shiva Shojaeian","doi":"10.2344/363591","DOIUrl":null,"url":null,"abstract":"Objective: To evaluate the anesthetic efficacy of 4% articaine with 1:100,000 epinephrine via primary intraosseous (IO) injection with the QuickSleeper device vs inferior alveolar nerve block (IANB) for mandibular first molars diagnosed with symptomatic irreversible pulpitis (SIP).Methods: Sixty-four patients with a first mandibular molar with SIP were randomly divided into 2 groups: IO (n = 32) and IANB (n = 32). Each received either an IO injection with the 5th generation QuickSleeper device or a conventional IANB with 1.7 mL 4% articaine with 1:100,000 epinephrine. Success was defined as no/mild pain upon the access cavity preparation and initial filing. Injection pain, anesthetic onset, heart rate (HR) change, HR recovery time, and duration of anesthesia were also recorded and analyzed.Results: The success rates were 40.6% for IANB and 81.2% for IO (P < .001). IO exhibited a significantly lower injection pain (P = .027), a shorter onset of action (P < .001), a greater heart rate increase (P < .001), a faster heart rate recovery time (P < .001), and a shorter duration of action (P < .001) vs IANB.Conclusion: Primary IO anesthesia using the fifth generation of the QuickSleeper device was more successful than IANB when using 4% articaine with 1:100,000 epinephrine to anesthetize mandibular first molars with SIP. The QuickSleeper device appeared to be a viable alternative to IANB for mandibular anesthesia.","PeriodicalId":94296,"journal":{"name":"Anesthesia progress","volume":"71 3","pages":"123-130"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11387966/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anesthesia progress","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2344/363591","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To evaluate the anesthetic efficacy of 4% articaine with 1:100,000 epinephrine via primary intraosseous (IO) injection with the QuickSleeper device vs inferior alveolar nerve block (IANB) for mandibular first molars diagnosed with symptomatic irreversible pulpitis (SIP).

Methods: Sixty-four patients with a first mandibular molar with SIP were randomly divided into 2 groups: IO (n = 32) and IANB (n = 32). Each received either an IO injection with the 5th generation QuickSleeper device or a conventional IANB with 1.7 mL 4% articaine with 1:100,000 epinephrine. Success was defined as no/mild pain upon the access cavity preparation and initial filing. Injection pain, anesthetic onset, heart rate (HR) change, HR recovery time, and duration of anesthesia were also recorded and analyzed.

Results: The success rates were 40.6% for IANB and 81.2% for IO (P < .001). IO exhibited a significantly lower injection pain (P = .027), a shorter onset of action (P < .001), a greater heart rate increase (P < .001), a faster heart rate recovery time (P < .001), and a shorter duration of action (P < .001) vs IANB.

Conclusion: Primary IO anesthesia using the fifth generation of the QuickSleeper device was more successful than IANB when using 4% articaine with 1:100,000 epinephrine to anesthetize mandibular first molars with SIP. The QuickSleeper device appeared to be a viable alternative to IANB for mandibular anesthesia.

查看原文本刊更多论文

QuickSleeper 骨内注射 4% 阿替卡因对下颌第一磨牙症状性不可逆牙髓炎的疗效：随机对照试验

目的评估在下颌第一磨牙诊断为症状性不可逆牙髓炎（SIP）时，使用QuickSleeper装置通过初次骨内注射（IO）4%阿替卡因与1:100,000肾上腺素与下牙槽神经阻滞（IANB）的麻醉效果：64名下颌第一磨牙SIP患者被随机分为两组：IO组（32人）和IANB组（32人）。每组患者都接受了使用第五代 QuickSleeper 装置的 IO 注射或使用 1.7 mL 4% 阿替卡因加 1:100,000 肾上腺素的传统 IANB 注射。成功的定义是在进入腔准备和初始锉磨时无/轻微疼痛。此外，还记录并分析了注射疼痛、麻醉开始时间、心率（HR）变化、心率恢复时间和麻醉持续时间：结果：IANB 的成功率为 40.6%，IO 为 81.2%（P < .001）。与 IANB 相比，IO 的注射疼痛明显降低（P = .027），起效时间更短（P < .001），心率上升幅度更大（P < .001），心率恢复时间更快（P < .001），起效时间更短（P < .001）：在使用 4% 阿替卡因和 1:100,000 肾上腺素对下颌第一磨牙进行 SIP 麻醉时，使用第五代 QuickSleeper 装置进行初级 IO 麻醉比 IANB 更成功。在下颌麻醉中，QuickSleeper 装置似乎是 IANB 的可行替代方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Anesthesia progress

自引率

0.00%

发文量